Document is current
Any future updates will be listed below
-
Authors
Zhang, Ziyan
Wang, Guanglei
Han, Fang
Zhou, Honghui
Liang, Yan
Zhang, Li
Pang, Ping
Cao, Xinyu
Hu, Peili
Yao, Xinyun
Sun, Chunhua
Wang, Jing
Shi, Xiuyu
Hu, Linyan
Yang, Guang
-
Funding
Funding for this research was provided by:
the general project of the National Key Research and Development Program of China (2023YFC2706405, 2022YFC2705300, 2022YFC2705302)
Capital’s Funds for Health Improvement and Research (2024-2-5082)
the key project of the Innovation Cultivation Fund of the Seventh Medical Center of Chinese PLA General Hospital (QZX-2023-1)
the Innovation Talent Fund of the Senior Department of Pediatrics, Seventh Medical Center of PLA General Hospital (QZX-04-EKLHJH-3)
- License Information
-
More Information
Article History
Received: 23 October 2025
Accepted: 29 May 2026
First Online: 19 June 2026
Declarations
:
: The study protocol was approved by the Ethical Committee of the First Medical Center of Chinese PLA General Hospital on 14th March 2024 (Approval No. S2023-681-02, Public title: Clinical study on multiple intravenous infusions of umbilical cord blood mononuclear cells to improve the therapeutic effect of autistic children with high expression of serum inflammatory factors) and conformed to the Declaration of Helsinki guidelines. All participants’ guardians provided written informed consent before recruitment. This study was registered on ChiCTR.org.cn on 7th April 2024 (Identifier: ChiCTR2400082762, Public title: Clinical study on multiple intravenous infusions of umbilical cord blood mononuclear cells to improve the therapeutic effect of autistic children with high expression of serum inflammatory factors).
: Informed written consent was obtained from all patients for publication of this report.
: The authors declare no competing interests.
